Grantham, Mayo, Van Otterloo & Co (GMO)
NGM

Grantham, Mayo, Van Otterloo & Co (GMO)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,397
Closed -$37.3K – 712
2023
Q2 		$37.3K Sell
14,397
-11,903
-45% -$42.5K ﹤0.01% 673
2023
Q1 		$107K Buy
+26,300
New +$122K ﹤0.01% 676

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s NGM Position: Q3 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 14,397 shares — an estimated $37.3K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NGM in Q1 2023 and held it in 2 quarters. The position peaked at $107K in Q1 2023. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 14,397 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $37.3K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $107K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2023, filed 13 Nov 2023.